The Polynovo Ltd (ASX: PNV) share price was one of the best performing ASX 200 healthcare shares in 2020, running from $1.97 to $3.88.
But when the company’s share price started to turn in the wrong direction, it fell and it fell fast.
It wasn’t just the trading update
Polynovo released a trading update on 12 January 2021 which saw its shares crash 13% on the day.
But it wasn’t just the trading update to point the finger at for Polynovo’s significant share price decline. Its shares had already slumped from $3.88 to $3.39 or 12% before the announcement, almost a tell tale of the bad news brewing.
Furthermore, the S&P/ASX 200 Health Care (ASX: XHJ) has also fallen 4.3% in the new year. Adding further insult to injury for the healthcare sector.
Bell Potter disappointed with first half FY21 trading update
Bell Potter reports: “Polynovo announced a relatively disappointing trading update, with 1H FY21 sales growth of 31% vs the pcp well below our forecasts, consensus and management expectations”.
In the company’s November 2020 annual general meeting, Polynovo’s NovoSorb BTM product experienced very strong growth from $9.3 million in FY19 to $19.06 million in FY20.
Polynovo managing director Paul Brennan said at the time the company would “continue to harness this momentum to double our revenues again in FY21”.
Bell Potter’s report notes that “expectations were broadly that sales would double in FY21 vs FY20”.
It noted that management also “tempered expectations around growth for the second half given the uncertainty in patient volumes”.
The broker did highlight some small positives including management’s strong update on new accounts, with successful customers additions and ongoing efforts to drive growth with integrated distribution networks. Those new customers may start to become more active users of Novosorb BTM in the coming months, especially if patient volumes recover well in a post-vaccine environment.
Overall, Bell Potter reduced its Polynovo share price target from $3.20 to $2.90 with a hold rating. The Polynovo share price is trading up 4.48% at $2.80 at the time of writing.
Our TOP healthcare stock is trading at a 30% discount to its highs
If there’s one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
Find out the name of this stock
As of 2.11.2020
More reading
- ASX 200 rises 0.1%
- ASX 200 down 0.3%: Altium sinks, Premier Investments rockets, energy shares rise
- Why Afterpay, Altium, Mesoblast, & PolyNovo shares are dropping lower
- ASX 200 drops lower
- ASX 200 up 0.4%: Altium disappoints, ARB impresses, Mesoblast charges higher
Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why this broker sees little upside to the Polynovo (ASX:PNV) share price right now appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3bzzOZy
Leave a Reply